Sompraz%25252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520hp

# Sompraz HP (Pantoprazole) ## Overview Pantoprazole is a proton pump inhibitor (PPI) that reduces the amount of acid produced in the stomach. ## Primary Indications * Healing of erosive esophagitis associated with gastroesophageal reflux disease (GERD). * Maintenance of healing of erosive esophagitis. * Treatment of pathological hypersecretory conditions, including Zollinger-Ellison Syndrome (ZES). ## Adult Dosing * **Healing of erosive esophagitis:** 40 mg orally or intravenously once daily for up to 8 weeks. * **Maintenance of healing of erosive esophagitis:** 40 mg orally once daily. * **Pathological hypersecretory conditions (e.g., ZES):** * **Oral:** Starting dose is typically 40 mg orally twice daily. Doses may be increased as needed. Doses up to 240 mg daily have been administered. * **Intravenous:** Starting dose is typically 80 mg intravenously once daily. Doses may be adjusted as needed. Doses up to 240 mg daily have been administered. ## Pediatric Dosing * **Erosive esophagitis (age 5 years and older):** 20 mg to 40 mg orally once daily for up to 8 weeks. * **GERD symptoms (age 5 years and older):** 20 mg orally once daily for up to 4 weeks. ## Dose Adjustments * **Hepatic impairment:** Maximum daily dose is 40 mg orally. ## Contraindications * Known hypersensitivity to pantoprazole or any of its components. ## Adverse Effects Common adverse effects include headache, diarrhea, nausea, abdominal pain, vomiting, dizziness, and arthralgia. ## Key Drug Interactions * **Drugs dependent on gastric pH for absorption:** PPIs can decrease the absorption of drugs that require an acidic gastric environment (e.g., ketoconazole, itraconazole, posaconazole, ampicillin esters, iron salts, vitamin B12). * **Methotrexate:** PPIs may increase serum levels of methotrexate. * **CYP2C19 substrates:** Pantoprazole is a moderate inhibitor of CYP2C19, which can affect the metabolism of certain drugs (e.g., clopidogrel, though clinical significance is debated). ## Monitoring * Monitor for signs and symptoms of infection (e.g., Clostridium difficile-associated diarrhea). * Monitor for bone fracture risk (long-term use). * Monitor for hypomagnesemia (long-term use). * Monitor for vitamin B12 deficiency (long-term use). ## Clinical Pearls * Administer oral pantoprazole 30 minutes before a meal. * Intravenous administration is typically reserved for patients unable to take oral medication. * Long-term PPI use may be associated with an increased risk of fractures, C. difficile infection, and hypomagnesemia. *** *This information is intended for healthcare professionals. Always consult the most current prescribing information and relevant clinical guidelines before making any treatment decisions. Dosing and recommendations may vary based on patient-specific factors and local protocols.*